Equity Overview
Price & Market Data
Price: $1.20
Daily Change: -$0.03 / 2.50%
Daily Range: $1.17 - $1.24
Market Cap: $13,464,613
Daily Volume: 83,021
Performance Metrics
1 Week: -11.85%
1 Month: -33.89%
3 Months: -7.03%
6 Months: -38.97%
1 Year: -70.01%
YTD: -61.74%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country:
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.